# Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

> **NCT05571267** · PHASE2 · TERMINATED · sponsor: **IVERIC bio, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Avacincaptad Pegol
- **DRUG:** Avastin
- **DRUG:** Lucentis
- **DRUG:** Eylea

## Key facts

- **NCT ID:** NCT05571267
- **Lead sponsor:** IVERIC bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-20
- **Primary completion:** 2018-04-24
- **Final completion:** 2018-04-24
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Following Sponsor reassessment, OPH2004 enrollment was stopped to initiate a new Zimura wet AMD trial, OPH2007, for treatment-naïve patients. Thus, only one patient was enrolled into and completed Study OPH2004.
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05571267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05571267, "Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05571267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*